Drugs that promote the healing of diabetic ulcers and their applications
The topical drug preparation made by using ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol and/or PPD-FS solves the problem of ineffective healing of diabetic ulcers in the existing technology, and achieves rapid and safe ulcer healing effect.
Patent Information
- Application Number
- CN202610616566.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-17
AI Technical Summary
Existing medications for treating diabetic ulcers, especially diabetic foot ulcers, are not effective in promoting ulcer healing and have issues with safety and efficacy.
Ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol and/or PPD-FS are used as active ingredients to prepare a topical drug preparation, which promotes the healing of diabetic ulcers through external application.
It significantly promotes the healing of diabetic ulcers, has a rapid effect, few toxic side effects, good safety, is suitable for various topical formulations, and is easy to promote.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention belongs to the field of medicine and relates to a drug that promotes the healing of diabetic ulcers. Background Technology
[0002] Diabetic ulcers typically include diabetic foot ulcers and diabetic leg ulcers, with the former being more common. Diabetic foot ulcer (DFU) is a foot ulcer and / or deep tissue destruction caused by distal lower extremity neuropathy and / or varying degrees of vascular disease due to diabetes, with or without infection. It is one of the most common and serious complications of diabetes, usually caused by multiple factors, including neuropathy, vascular disease, and foot infection. Its main manifestations include: numbness and coldness in the foot, swelling or purplish discoloration, decreased sensation, pain, ulceration and gangrene, decreased resistance to infection, slow or non-healing wounds leading to necrosis and amputation. As of 2024, there were over 550 million people with diabetes worldwide, and nearly 35 million with DFU. The average prevalence of DFU in China is 8.1%, with a lifetime prevalence of approximately 30%. As of 2024, there were over 125 million people with diabetes in China, and nearly 10.13 million with DFU. The global amputation rate for diabetic foot ulcer patients is 31%, meaning that every minute, 3 diabetic foot ulcer patients undergo amputation or toe amputation due to foot ulcers.
[0003] Unlike skin lesions caused by diabetes, diabetic foot ulcers are more difficult to heal due to long-term high blood sugar levels, leading to lower limb neuropathy and microvascular disease. Foot tissue ischemia / malnutrition, impaired nerve function, and insufficient nutrient and oxygen supply to the wound result in a slow healing process. The development of diabetic foot indicates a long history of diabetes and inadequate foot care. Even after ulceration, recurrence is highly likely if patients do not control their blood sugar, improve foot blood circulation, and wear appropriate footwear. Deep ulcers or those accompanied by severe infection and necrosis, with multiple complications, can lead to serious osteomyelitis and sepsis, increasing the difficulty and risk of treatment and potentially requiring surgical procedures such as debridement and flap transplantation. Currently, clinical treatment often involves oral hypoglycemic agents and antibiotics or surgery, which can only prevent the worsening of diabetic foot and increase the physiological and economic burden on patients. While oral hypoglycemic agents can temporarily control blood sugar, they cannot completely prevent the progression of the disease and the occurrence of complications. For patients with diabetic foot ulcers, improving blood circulation and nutrition in the feet and effectively promoting wound healing has become a key focus of international new drug research and development. Developing highly effective and low-toxicity drugs or health products with new mechanisms of action or new structural types to promote the healing of diabetic foot ulcers has become a key focus of international new drug research and development.
[0004] Ginseng is a precious traditional Chinese medicine. Modern medical research shows that the main effects and functions of ginseng include: effects on the central nervous system, anti-cancer and anti-tumor effects, immune function regulation, anti-diabetic effects, liver function enhancement, improvement of cardiovascular and cerebrovascular disorders, anti-arteriosclerosis effects, blood pressure regulation, menopausal disorders and anti-osteoporosis effects, anti-fatigue, anti-oxidation, and anti-aging effects. Li Jingping et al. (Yunnan Journal of Traditional Chinese Medicine and Materia Medica, 2016, 37(1):25) preliminarily explored the effect of ginsenoside Rg3 in promoting wound healing in diabetic rats. However, the large dose of 150mg / kg / d administered via the digestive tract, and the broad physiological effects of ginsenoside Rg3 itself, make its safety difficult to guarantee, and it has not been clinically promoted.
[0005] Through long-term and arduous research, the inventors discovered that external application of ginseng extract can promote the healing of diabetic foot ulcers. After further repeated research and screening, a topical drug preparation was prepared using ginsenoside Rg3 / ginsenoside Rh2 / protopanaxadiol and / or PPD-FS (protopanaxadiol group saponin extract) as active ingredients, which can effectively treat diabetic ulcers. Summary of the Invention
[0006] The purpose of this invention is to address the technical problems existing in current drugs for treating diabetic ulcers and to provide a new drug, pharmaceutical preparation, and treatment method for treating diabetic ulcers. This invention provides the performance and efficacy of ginseng extracts ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol, and / or PPD-FS for external use in treating diabetic ulcers, and provides new pharmaceutical uses for ginseng extracts, representing a new application in drugs for treating diabetic ulcers.
[0007] To achieve the objectives of this invention, one aspect of this invention provides a drug for promoting the healing of diabetic ulcers, wherein the drug is one or more of ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol, or PPD-FS (protopanaxadiol group saponin extract).
[0008] Among them, ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol and / or PPD-FS can be all the therapeutic active ingredients.
[0009] In particular, diabetic ulcers are diabetic foot ulcers or diabetic leg ulcers, with diabetic foot ulcers being preferred. Diabetic foot ulcers are foot infections, ulcers, and / or deep tissue destruction caused by distal lower extremity nerve abnormalities and varying degrees of vascular disease in diabetic patients.
[0010] In this document, ginsenoside Rg3 refers to 20(S)-ginsenoside Rg3, 20(R)-ginsenoside Rg3, or a mixture thereof. In embodiments of the present invention, ginsenoside Rg3 is a mixture of 20(S)-ginsenoside Rg3 and 20(R)-ginsenoside Rg3 in a ratio of approximately 1:1.
[0011] In this document, ginsenoside Rh2 refers to 20(S)-ginsenoside Rh2, 20(R)-ginsenoside Rh2, or a mixture thereof. In embodiments of the present invention, ginsenoside Rh2 is a mixture of 20(S)-ginsenoside Rh2 and 20(R)-ginsenoside Rh2 in a ratio of approximately 1:1.
[0012] In this document, protopanaxadiol refers to 20(S)-protopanaxadiol, 20(R)-protopanaxadiol, or a mixture thereof. In embodiments of the present invention, protopanaxadiol is a mixture of 20(S)-protopanaxadiol and 20(R)-protopanaxadiol in a ratio of approximately 1:1.
[0013] The drug is a composition of ginsenoside Rg3 and ginsenoside Rh2, wherein the weight ratio of ginsenoside Rg3 to ginsenoside Rh2 is (60~99):(40~1), preferably (75-85):(15-25).
[0014] The PPD-FS includes ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rh2, wherein the weight ratio of ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rh2 is (60-95):(3-35):(2-5), preferably (75-85):(7-33):(3-5).
[0015] In this invention, the preparation method of PPD-FS includes: ginseng, Panax notoginseng, American ginseng, Gynostemma pentaphyllum, and other medicinal materials containing protopanaxadiol saponins are steamed, then extracted with an extraction solvent by cold soaking or reflux extraction; the extracts are combined and a minimum amount is recovered under reduced pressure, then filtered, and the filtrate is loaded onto an HDP-100 macroporous resin column and eluted with 40% ethanol (V / V) until the eluent is colorless and protopanaxadiol-type saponin—ginsenoside Rg3—appears in the eluent by thin-layer chromatography. Elution is then continued with 60% ethanol (V / V), and the 60% ethanol (V / V) eluent is collected and recovered to dryness under reduced pressure, or further recrystallized to obtain PPD-FS with a content of 60%-99% (the content is calculated as the sum of ginsenoside Rg3, ginsenoside Rg5, and ginsenoside Rh2).
[0016] In particular, the content ratio of ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rh2 in the PPD-FS is (60-95):(3-35):(2-5).
[0017] The steaming process is a conventional steaming method in the field of traditional Chinese medicine, and a conventional processing method for Chinese medicinal materials.
[0018] In particular, the extraction solvent is a conventional extraction solvent such as water, methanol, ethanol, aqueous methanol or aqueous ethanol.
[0019] In particular, the reduced pressure recovery is at least 10-20% of the total volume of the recovered liquid after combining.
[0020] In particular, if methanol, ethanol, aqueous methanol or aqueous ethanol are used as extraction solvents for cold soaking or reflux extraction, the concentration of methanol or ethanol in the recovered solution is less than 30%.
[0021] In a specific embodiment of the present invention, the preparation method of PPD-FS includes:
[0022] 1) After steaming the ginseng, heat and reflux it 1-3 times with a 75% (V / V) ethanol aqueous solution. Combine the hot reflux extracts, recover the ethanol until the ethanol concentration is below 30% (usually 5-40%), and filter.
[0023] 2) The filtrate is loaded onto a macroporous resin column (preferably HDP-100 macroporous resin) and eluted with 40% ethanol aqueous solution (V / V) until the eluent is colorless. Thin-layer chromatography is used to detect the appearance of protopanaxadiol-type saponins (i.e., ginsenoside Rg3) in the eluent. Then, elute with 60% (V / V) ethanol aqueous solution for 10 column volumes, collect the 60% (V / V) ethanol aqueous solution eluent, recover the solvent from the collected eluent, and directly dry or recrystallize with water or alcohol solution to obtain PPD-FS with different contents.
[0024] In particular, in step 1), the weight ratio of human ginseng to ethanol aqueous solution is 1:(8-20) during each heating and reflux extraction process.
[0025] In particular, the extraction time for each heating and reflux extraction is 1-3 hours.
[0026] In particular, the drug also includes one or more of the following: Angelica sinensis extract, dragon's blood extract, Astragalus membranaceus extract, Curcuma longa extract, Taraxacum mongolicum extract, Lithospermum erythrorhizon extract, Piper nigrum extract, Lonicera japonica extract, and Grape seed extract.
[0027] Another aspect of the present invention provides the use of ginseng extract in the preparation of a medicament for treating diabetic ulcers, wherein the ginseng extract is one or more of ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol, or PPD-FS.
[0028] In particular, the present invention also provides the use of one or more of ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol and / or PPD-FS in the preparation of a topical medicine for treating diabetic ulcers.
[0029] In particular, the diabetic ulcer is a diabetic foot ulcer or a diabetic leg ulcer, preferably a diabetic foot ulcer.
[0030] In particular, the drug is composed of one or more of ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol or PPD-FS and a pharmaceutically acceptable carrier.
[0031] In particular, ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol and / or PPD-FS can be all the active pharmaceutical ingredients of the topical medicine.
[0032] In particular, the drug exists in the form of powder, lotion, solution, cream, ointment, suspension, spray, aerosol, gel, film or patch.
[0033] In particular, the medication is a topical preparation. It is applied to the ulcers of patients with diabetic ulcers.
[0034] The pharmaceutically acceptable carrier in the topical formulation of the present invention is a pharmaceutically acceptable carrier suitable for formulating the topical formulation.
[0035] Pharmaceutically acceptable carriers are generally approved by healthcare professionals for use in this purpose and as inactive ingredients in pharmaceutical preparations. Compilations of pharmaceutically acceptable carriers can be found in reference books such as the *Handbook of Pharmaceutical Excipients* (2nd edition, edited by A. Wade and P. J. Weller; published by the American Pharmaceutical Association, Washington and The Pharmaceutical Press, London, 1994).
[0036] In particular, the carrier includes excipients such as starch and water; lubricants such as magnesium stearate; disintegrants such as microcrystalline cellulose; fillers such as lactose; binders such as pregelatinized starch and dextrin; sweeteners; antioxidants; preservatives, flavoring agents, and fragrances.
[0037] In particular, it also includes excipients, which are one or more of the following: water, glycerin, propylene glycol, ethanol, carbomer, beeswax, sodium cetearyl sulfate, benzyl alcohol, oleic acid, glyceryl triglyceride, sesame oil, cetyl alcohol, octadecyl alcohol, glyceryl mono- and distearyl esters, hydroxypropyl methylcellulose E5, gelatin, β-hydroxypropyl cyclodextrin, glycerin, ethylparaben, sodium alginate, acrylic pressure-sensitive adhesive, butylated hydroxytoluene, and glyceryl monooleate, preferably a carbomer hydrogel matrix.
[0038] The weight ratio of ginseng extract to the total weight of the topical preparation of the present invention can be 0.01 to 10:100, wherein the ginseng extract is one or more of ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol or PPD-FS.
[0039] In particular, the ginseng extract is a composition of ginsenoside Rg3 and ginsenoside Rh2, wherein the weight ratio of ginsenoside Rg3 to ginsenoside Rh2 is (60~99):(40~1), preferably (75-85):(15-25).
[0040] In particular, the ginseng extract is PPD-FS, wherein PPD-FS includes ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rh2, wherein the weight ratio of ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rh2 is (60-95):(3-35):(2-5), preferably (75-85):(7-33):(3-5).
[0041] The present invention relates to a method for treating diabetic ulcers by applying to the ulcer site one or more of the following: ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol, or PPD-FS. Preferably, the method involves applying to the ulcer site a therapeutically effective amount of ginsenoside Rg3; applying to the ulcer site a combination of ginsenoside Rg3 and ginsenoside Rh2; applying to the ulcer site a therapeutically effective amount of protopanaxadiol; or applying to the ulcer site a therapeutically effective amount of PPD-FS.
[0042] Unless otherwise stated, the term “therapeutic effective dose” as used herein refers to the dosage of a drug required to produce an effective effect; “therapeutic effective dose” is subject to adjustment and variation and is ultimately determined by healthcare professionals, taking into account factors such as the route of administration and the nature of the formulation, the recipient’s weight, age and other general characteristics, as well as the nature and severity of the disease being treated.
[0043] The treatment method of the present invention may include applying a therapeutically effective amount of protopanaxadiol and PPD-FS to the ulcer site of a patient in need. Preferably, the treatment method of the present invention includes applying a therapeutically effective amount of a combination of ginsenoside Rg3 and Rh2 and PPD-FS to the ulcer site of a patient in need.
[0044] The treatment method of the present invention includes applying a therapeutically effective amount of a combination of ginsenoside Rg3 and ginsenoside Rh2 to the ulcer of a patient, wherein the weight ratio of ginsenoside Rg3 to ginsenoside Rh2 is (60~99):(40~1), preferably (75-85):(15-25).
[0045] The treatment method of the present invention includes applying a therapeutically effective amount of PPD-FS to the ulcer of a patient, wherein the PPD-FS comprises ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rh2, wherein the weight ratio of ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rh2 is (60-95):(3-35):(2-5), preferably (75-85):(7-33):(3-5).
[0046] The ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol and / or PPD-FS used in the treatment method of the present invention can be included in the pharmaceutical preparation.
[0047] In another aspect, the present invention provides a topical preparation for treating diabetic ulcers, comprising one or more of ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol or PPD-FS, and a pharmaceutically acceptable carrier.
[0048] Ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol and / or PPD-FS can be all the active pharmaceutical ingredients. That is, the topical preparation of the present invention is composed of ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol and / or PPD-FS, and a pharmaceutically acceptable carrier.
[0049] Compared with the prior art, the present invention has the following obvious advantages:
[0050] 1. This invention has discovered new medicinal values for known compounds such as ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol and / or PPD-FS, and has used them to promote the healing of diabetic foot ulcers. They can also be prepared into drugs or health foods for promoting the healing of diabetic foot ulcers, thus opening up a new field for the application of ginseng medicinal materials.
[0051] 2. The series of experimental studies of the present invention have demonstrated that ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol and / or PPD-FS have significant effects in promoting the healing of diabetic foot ulcers. In particular, the combination of ginsenoside Rg3 and ginsenoside Rh2 and PPD-FS have significant effects and have a synergistic effect.
[0052] 3. The ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol and / or PPD-FS of the present invention have strong pharmacological effects, are significantly effective in promoting the healing of diabetic foot ulcers, have rapid effects, few toxic side effects, good safety, and have good medicinal prospects.
[0053] 4. The raw materials of the product of this invention are abundant, safe for clinical use, and the preparation process is simple. It can be made into various external dosage forms and is convenient to use, so it is easy to promote. Attached Figure Description
[0054] Figure 1 The images show photographs of the affected area in Case 1 during the early (Fig. a), middle (Fig. b), and late (Fig. c) stages of treatment with the drug of the present invention.
[0055] Figure 2 The images show photographs of the affected area in Case 2 after receiving the drug of the present invention for 0 days (Fig. a), 1 week (Fig. b), 2 weeks (Fig. c), and 3 weeks (Fig. d).
[0056] Figure 3 The images show photographs of the affected area in Case 3 after receiving the drug treatment of the present invention (Fig. a), intermediate (Fig. b), and late (Fig. c).
[0057] Figure 4 The images show photographs of the affected area in Case 4 before (Fig. a) and after (Fig. b) treatment with the drug of the present invention.
[0058] Figure 5 The images show photographs of the affected area in Case 5 before (Fig. a) and after (Fig. b) treatment with the drug of the present invention. Detailed Implementation
[0059] The beneficial effects of the formulation described in this invention will be further described below through specific embodiments. These embodiments are merely exemplary and do not constitute any limitation on the scope of this invention. Those skilled in the art should understand that modifications or substitutions can be made to the details and form of the technical solution of this invention without departing from the formulation concept and scope of application of this invention, but all such modifications and substitutions fall within the protection scope of this invention.
[0060] Example 1: Preparation method of PPD-FS
[0061] 4 kg of ginseng was steamed for 80 ± 1 h and cooled to room temperature before adding 48 L of 75% (V / V) ethanol. The mass ratio of ginseng to ethanol was 1:12 (usually 1:(8-20)). The extraction time was 2 h (usually 1-3 h).
[0062] The steaming process is a conventional method for processing ginseng medicinal materials in the art; the amount of ethanol added during the extraction process is the conventional amount used in the art.
[0063] The ginseng is extracted by heating and reflux three times (usually two to four times); the reflux extracts are combined; the total extract is then subjected to vacuum recovery until the ethanol concentration is below 30% (usually 5-40%) to obtain a concentrated ginseng extract.
[0064] After the ginseng concentrate was cooled to room temperature, it was filtered. The filtrate was added to an HDP-100 macroporous resin column and eluted with 40% ethanol (v / v) until the eluent was colorless. When Rg3 was just detected by thin-layer chromatography, it was eluted with 60% ethanol (v / v) for 10 column volumes. The eluent eluted with 60% ethanol was collected to obtain a mixture of protopanaxadiol saponins. One-quarter of the mixture was taken and dried under reduced pressure to obtain 36g of PPD-FS A, in which the content ratio of Rg3, Rg5, and Rh2 was 60:35:5, and the sum of the three contents was 60%.
[0065] Take 1 / 4 of the mixture and reduce the pressure until there is no alcohol odor. Cool, precipitate, filter, and obtain 28g of PPD-FS B, in which the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%.
[0066] Take 1 / 4 of the mixture and recover it under reduced pressure until there is no alcohol odor. Cool it, precipitate it, filter it, and recrystallize the precipitate once with ethanol to obtain 24g of PPD-FS C, in which the content ratio of Rg3, Rg5 and Rh2 is 85:13:2, and the sum of the contents of the three is 85%.
[0067] Take 1 / 4 of the mixture and recover it under reduced pressure until there is no alcohol odor. Cool it, precipitate it, filter it, and recrystallize the precipitate twice with ethanol to obtain 21g of PPD-FS D, in which the content ratio of Rg3, Rg5 and Rh2 is 95:3:2 and the sum of the contents of the three is 99%.
[0068] The PPD-FS of the present invention, which promotes the healing of diabetic ulcers, contains Rg3, Rg5, and Rh2, wherein the weight ratio of Rg3, Rg5, and Rh2 is as follows: (60-95):(3-35):(2-5); preferably (75-85):(7-33):(3-5).
[0069] In this invention, the protopanaxadiol saponin extract (PPD-FS) refers to a mixture containing a high proportion of protopanaxadiol saponins such as Rg3, Rg5, and Rh2, obtained by using resin column separation to initially separate protopanaxadiol saponins and protopanaxadiol saponins in the herbal extract, with a ratio of (60-95):(3-35):(2-5) and a total content of more than 60%.
[0070] Example 2: Preparation method of PPD-FS
[0071] 3 kg of Panax notoginseng medicinal material is steamed for 80 ± 1 h and cooled to room temperature. Then, 60 L of 75% (V / V) ethanol is added. The mass ratio of Panax notoginseng medicinal material to the volume ratio of ethanol is 1:20 (usually 1:(8-20)).
[0072] The steaming process is a conventional method for processing Panax notoginseng in this field.
[0073] The extraction process was repeated three times by heating and reflux; the reflux extracts were combined; the total extract was subjected to vacuum recovery treatment until the ethanol concentration was below 30% (usually 5-40%), thus obtaining a concentrated Panax notoginseng extract.
[0074] After the concentrated extract of Panax notoginseng was cooled to room temperature, it was filtered. The filtrate was added to an HDP-100 macroporous resin column and eluted with 40% ethanol (V / V) until the eluent was colorless and Rg3 was just detected by thin-layer chromatography. Then, it was eluted with 60% ethanol (V / V) and the eluent eluted with 60% ethanol was collected to obtain a mixture of protopanaxadiol saponins.
[0075] One-third of the mixture was taken and dried under reduced pressure to obtain 41g of PPD-FS E, in which the content ratio of Rg3, Rg5 and Rh2 was 61:33:6, and the sum of the contents of the three was 66%.
[0076] Take 1 / 3 of the mixture and recover it under reduced pressure until there is no alcohol odor. Cool it and filter it to obtain 29g of PPD-FS F, in which the content ratio of Rg3, Rg5 and Rh2 is 70:25:5 and the sum of the contents of the three is 81%.
[0077] Take 1 / 3 of the mixture and recover it under reduced pressure until there is no alcohol odor. Cool it, filter it, and recrystallize the precipitate once with ethanol to obtain 22g of PPD-FSG, in which the content ratio of Rg3, Rg5 and Rh2 is 90:7:3 and the sum of the contents of the three is 89%.
[0078] Example 3: Ginsenoside Rg3 gel
[0079] 1. Prepare the raw materials according to the following proportions.
[0080] Ginsenoside Rg3 10 g
[0081] Carbomer 50 g
[0082] 100 g of glycerin
[0083] 50 g of triethanolamine
[0084] Add water to 1000 ml
[0085] 2. Mix ginsenoside Rg3 with carbomer, glycerin, and 60% water until completely dissolved to form a solution. Add triethanolamine and 40% water and mix well to obtain ginsenoside gel.
[0086] Example 4: Ginsenoside Rg3 Cream
[0087] 1. Prepare the raw materials according to the following proportions.
[0088] Ginsenoside Rg3 10 g
[0089] Aqueous phase
[0090] Sodium hexadecyl sulfate 20 g
[0091] 100 g of propylene glycol
[0092] 5 g of benzyl alcohol
[0093] 595 g of purified water
[0094] oil phase
[0095] 170 g of oleic acid
[0096] 40 g of cyclophosphamide triglyceride
[0097] Cetyl alcohol 50 g
[0098] 50 g of stearyl alcohol
[0099] Glyceryl monostearate and glyceryl distearate) 50 g
[0100] 2. Add the aqueous phase to the oil phase, stir, and then add ginsenoside Rg3 to obtain the final product.
[0101] Example 5: Ginsenoside Rg3 film-forming agent
[0102] 1. Prepare the raw materials according to the following proportions.
[0103] Ginsenoside Rg3 10 g
[0104] Hydroxypropyl methylcellulose E5 230 g
[0105] 80 g of gelatin
[0106] 200 g of propylene glycol
[0107] 2500 g of purified water
[0108] 2. Mix ginsenoside Rg3, hydroxypropyl methylcellulose E5, propylene glycol, and purified water evenly to make a solution, let it stand overnight, and then coat it with a film to obtain the final product.
[0109] Example 6: Ginsenoside Rg3 Spray
[0110] 1. Prepare the raw materials according to the following proportions.
[0111] Ginsenoside Rg3 10 g
[0112] β-hydroxypropyl-cyclodextrin 430 g
[0113] Add purified water to 100,000 ml
[0114] 2. Ginsenoside Rg3 and β-hydroxypropyl-cyclodextrin are encapsulated and dissolved in water to obtain the product.
[0115] Example 7: Ginsenoside Rg3 Solution
[0116] 1. Prepare the raw materials according to the following proportions.
[0117] Ginsenoside Rg3 10 g
[0118] β-hydroxypropyl-cyclodextrin 430 g
[0119] 1000 g of glycerin
[0120] 10 g of ethylparaben
[0121] Add purified water to 10000 ml
[0122] 2. Ginsenoside Rg3, β-hydroxypropyl-cyclodextrin, glycerol, and ethylparaben are encapsulated and dissolved in water to obtain the final product.
[0123] Example 8: Ginsenoside Rg3 Powder
[0124] 1. Prepare the raw materials according to the following proportions.
[0125] Ginsenoside Rg3 10 g
[0126] 1 g sodium alginate
[0127] Repackaged into 10,000 portions
[0128] 2. Mix ginsenoside Rg3 and sodium alginate evenly, then package them into portions.
[0129] Example 9: Ginsenoside Rg3 Patch
[0130] 1. Prepare the raw materials according to the following proportions.
[0131] Ginsenoside Rg3 10 g
[0132] Acrylic pressure-sensitive adhesive TAK87-4098 685 g
[0133] 5 g of butylated hydroxytoluene
[0134] 50 g of glyceryl monooleate
[0135] Ethanol (appropriate amount)
[0136] 2. Add acrylic pressure-sensitive adhesive TAK87-4098, butylated hydroxytoluene, and glyceryl monooleate to an appropriate amount of ethanol and stir thoroughly until completely dissolved. Add ginsenoside Rg3 and stir evenly to obtain a drug-containing layer. Coat the drug-containing layer onto a protective layer (a polyethylene release film treated with dimethyl silicone oil), and dry at 40°C for 15 minutes to remove organic solvents. After drying, cover with a backing layer (a synthetic resin film of polyethylene, polypropylene, and polyvinyl chloride), and then cut into patches of the required size to obtain the final product.
[0137] Example 10: Ginsenoside composition gel
[0138] 1. Prepare the raw materials according to the following proportions.
[0139] Ginsenoside Rg3 7.5 g
[0140] Ginsenoside Rh2 2.5 g
[0141] Carbomer 50 g
[0142] 100 g of glycerin
[0143] 50 g of triethanolamine
[0144] Add water to 1000 ml
[0145] 2. Mix Rg3, Rh2, carbomer, glycerin, and 60% water until completely dissolved to form a solution. Add triethanolamine and 40% water and mix well to obtain ginsenoside gel, wherein the weight ratio of ginsenoside Rg3 to ginsenoside Rh2 is 75:25.
[0146] Example 11: Ginsenoside Composition Cream
[0147] 1. Prepare the raw materials according to the following proportions.
[0148] Ginsenoside Rg3 8.6g
[0149] Ginsenoside Rh2 1.4g
[0150] Aqueous phase:
[0151] Sodium hexadecyl sulfate 20g
[0152] 100g of propylene glycol
[0153] 5g of benzyl alcohol
[0154] 595g of purified water
[0155] Oil phase:
[0156] 170g of oleic acid
[0157] 40g of cyclophosphamide triglyceride
[0158] Cetyl alcohol 50g
[0159] 50g of stearyl alcohol
[0160] Glyceryl monostearate and glyceryl distearate) 50g
[0161] 2. Add the aqueous phase to the oil phase, stir, and add Rg3 and Rh2 to obtain the final product.
[0162] Example 12: Ginsenoside Composition Film Formulation
[0163] 1. Prepare the raw materials according to the following proportions.
[0164] Ginsenoside Rg3 6.8g
[0165] Ginsenoside Rh2 3.2g
[0166] Hydroxypropyl methylcellulose E5 430g
[0167] 200g of propylene glycol
[0168] 2500g of purified water
[0169] 2. Mix Rg3, Rh2, hydroxypropyl methylcellulose E5, propylene glycol, and purified water evenly to make a solution, let it stand overnight, and then coat it with a film to obtain the final product.
[0170] Example 13 Ginsenoside Composition Spray
[0171] 1. Prepare the raw materials according to the following proportions.
[0172] Ginsenoside Rg3 9.9 g
[0173] Ginsenoside Rh2 0.1 g
[0174] β-hydroxypropyl-cyclodextrin 430 g
[0175] Add purified water to 100,000 ml
[0176] 2. The product is obtained by encapsulating Rg3, Rh2 and β-hydroxypropyl-cyclodextrin and dissolving them in water.
[0177] Example 14 Ginsenoside Composition Solution
[0178] 1. Prepare the raw materials according to the following proportions.
[0179] Ginsenoside Rg3 6g
[0180] Ginsenoside Rh2 4g
[0181] β-hydroxypropyl-cyclodextrin 430 g
[0182] 1000 g of glycerin
[0183] 10 g of ethylparaben
[0184] Add purified water to 10000 ml
[0185] 2. Rg3, Rh2, β-hydroxypropyl-cyclodextrin, glycerol, and ethylparaben are encapsulated and dissolved in water to obtain the final product.
[0186] Example 15: Ginsenoside Composition Powder
[0187] 1. Prepare the raw materials according to the following proportions.
[0188] Ginsenoside Rg3 5.8 g
[0189] Ginsenoside Rh2 4.2 g
[0190] 1 g sodium alginate
[0191] Repackaged into 10,000 portions
[0192] 2. Mix Rg3, Rh2 and sodium alginate evenly, and then package them into portions.
[0193] Example 16 Ginsenoside Composition Patch
[0194] 1. Prepare the raw materials according to the following proportions.
[0195] Ginsenoside Rg3 5.8g
[0196] Ginsenoside Rh2 4.2g
[0197] Acrylic pressure-sensitive adhesive TAK87-4098 685 g
[0198] 5 g of butylated hydroxytoluene
[0199] 50 g of glyceryl monooleate
[0200] Ethanol (appropriate amount)
[0201] 2. Add acrylic pressure-sensitive adhesive TAK87-4098, butylated hydroxytoluene, and glyceryl monooleate to an appropriate amount of ethanol and stir thoroughly until completely dissolved. Add Rg3 and Rh2, and stir evenly to obtain a drug-containing layer. Coat the drug-containing layer onto a protective layer (a polyethylene release film treated with dimethyl silicone oil), and dry at 40°C for 15 minutes to remove organic solvents. After drying, cover with a backing layer (a synthetic resin film of polyethylene, polypropylene, and polyvinyl chloride), and then cut into patches of the required size to obtain the final product.
[0202] Example 17: Ginsenoside Diol Gel
[0203] 1. Prepare the raw materials according to the following proportions.
[0204] 10 g of protopanaxadiol
[0205] Carbomer 50 g
[0206] 100 g of glycerin
[0207] 50 g of triethanolamine
[0208] Add water to 1000 ml
[0209] 2. Mix ginsenoside diol, carbomer, glycerin, and an appropriate amount of water until completely dissolved to form a solution. Add triethanolamine and an appropriate amount of water and mix well. Adjust the volume to 1000ml to obtain ginsenoside gel.
[0210] Example 18: Ginsenoside Diol Cream
[0211] 1. Prepare the raw materials according to the following proportions.
[0212] 10g of protopanaxadiol
[0213] Aqueous phase:
[0214] Sodium hexadecyl sulfate 20g
[0215] 100g of propylene glycol
[0216] 5g of benzyl alcohol
[0217] 595g of purified water
[0218] Oil phase:
[0219] 170g of oleic acid
[0220] 40g of cyclophosphamide triglyceride
[0221] Cetyl alcohol 50g
[0222] 50g of stearyl alcohol
[0223] Glyceryl monostearate and glyceryl distearate) 50g
[0224] 2. Add the aqueous phase to the oil phase, stir, and then add protopanaxadiol to obtain the final product.
[0225] Example 19: Ginsenoside Diol Film Formulation
[0226] 1. Prepare the raw materials according to the following proportions.
[0227] 10 g of protopanaxadiol
[0228] Hydroxypropyl methylcellulose E5 430 g
[0229] 200 g of propylene glycol
[0230] 2500 g of purified water
[0231] 2. Mix ginsenoside diol, hydroxypropyl methylcellulose E5, propylene glycol, and purified water evenly to make a solution, let it stand overnight, and then coat it with a film to obtain the final product.
[0232] Example 20: Ginsenoside Diol Spray
[0233] 1. Prepare the raw materials according to the following proportions.
[0234] 10 g of protopanaxadiol
[0235] β-hydroxypropyl-cyclodextrin 430 g
[0236] Add purified water to 100,000 ml
[0237] 2. The original ginsenoside diol and β-hydroxypropyl-cyclodextrin are encapsulated and dissolved in water to obtain the final product.
[0238] Example 21: Ginsenoside Diol Solution
[0239] 1. Prepare the raw materials according to the following proportions.
[0240] 10 g of protopanaxadiol
[0241] β-hydroxypropyl-cyclodextrin 430 g
[0242] 1000 g of glycerin
[0243] 10 g of ethylparaben
[0244] Add purified water to 10000 ml
[0245] 2. The original ginsenoside diol, β-hydroxypropyl-cyclodextrin, glycerol, and ethylparaben are encapsulated and dissolved in water to obtain the final product.
[0246] Example 22: Original Ginsenoside Diol Powder
[0247] 1. Prepare the raw materials according to the following proportions.
[0248] 10 g of protopanaxadiol
[0249] 1 g sodium alginate
[0250] Repackaged into 10,000 portions
[0251] 2. Mix the original ginsenoside diol and sodium alginate evenly, then package them into portions to obtain the final product.
[0252] Example 23: Ginsenoside Diol Patch
[0253] 1. Prepare the raw materials according to the following proportions.
[0254] 10 g of protopanaxadiol
[0255] Acrylic pressure-sensitive adhesive TAK87-4098 685 g
[0256] 5 g of butylated hydroxytoluene
[0257] 50 g of glyceryl monooleate
[0258] Ethanol (appropriate amount)
[0259] 2. Add acrylic pressure-sensitive adhesive TAK87-4098, butylated hydroxytoluene, and glyceryl monooleate to an appropriate amount of ethanol and stir thoroughly until completely dissolved. Add protopanaxadiol and stir evenly to obtain a drug-containing layer. Coat the drug-containing layer onto a protective layer (a polyethylene release film treated with dimethyl silicone oil) and dry at 40°C for 15 minutes to remove organic solvents. After drying, cover with a backing layer (a synthetic resin film of polyethylene, polypropylene, and polyvinyl chloride), and then cut into patches of the required size to obtain the final product.
[0260] Example 24 PPD-FS Gel
[0261] 1. Prepare the raw materials according to the following proportions.
[0262] PPD-FS 10 g
[0263] Carbomer 50 g
[0264] 100 g of glycerin
[0265] 50 g of triethanolamine
[0266] PPD-FS was prepared according to the method in Example 1 for PPD-FS B (where the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%).
[0267] Mix PPD-FS, carbomer, glycerin and an appropriate amount of water until completely dissolved to make a solution. Add an aqueous solution of triethanolamine and mix well. Then add water to a total volume of 1000 ml to obtain ginsenoside gel.
[0268] Example 25 PPD-FS Gel
[0269] 1. Prepare the raw materials according to the following proportions.
[0270] PPD-FS 5 g
[0271] Carbomer 8 g
[0272] 100 g of glycerin
[0273] Triethanolamine 8 g
[0274] PPD-FS was prepared according to the method in Example 1 for PPD-FS B (where the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%).
[0275] 2. Mix PPD-FS, carbomer, glycerin and an appropriate amount of water until completely dissolved to make a solution. Add triethanolamine aqueous solution and mix well. Add water to 1000 ml to obtain ginsenoside gel (concentration of 5 mg / ml).
[0276] Example 26 PPD-FS Gel
[0277] 1. Prepare the raw materials according to the following proportions.
[0278] PPD-FS 3 g
[0279] Carbomer 6 g
[0280] 100 g of glycerin
[0281] Triethanolamine 6g
[0282] PPD-FS was prepared according to the method in Example 1 for PPD-FS B (where the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%).
[0283] 2. Mix PPD-FS, carbomer, glycerin and an appropriate amount of water until completely dissolved to make a solution. Add triethanolamine aqueous solution and mix well. Add water to 1000 ml to obtain ginsenoside gel (concentration of 3 mg / ml).
[0284] Example 27 PPD-FS Gel
[0285] 1. Prepare the raw materials according to the following proportions.
[0286] PPD-FS 1 g
[0287] Carbomer 4 g
[0288] 100 g of glycerin
[0289] Triethanolamine 4g
[0290] PPD-FS was prepared according to the method in Example 1 for PPD-FS B (where the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%).
[0291] 2. Mix PPD-FS, carbomer, glycerin and an appropriate amount of water until completely dissolved to make a solution. Add triethanolamine aqueous solution and mix well. Add water to 1000 ml to obtain ginsenoside gel (concentration of 1 mg / ml).
[0292] Example 28 PPD-FS Cream
[0293] 1. Prepare the raw materials according to the following proportions.
[0294] PPD-FS 10g
[0295] Aqueous phase:
[0296] Sodium hexadecyl sulfate 20g
[0297] 100g of propylene glycol
[0298] 5g of benzyl alcohol
[0299] 595g of purified water
[0300] Oil phase:
[0301] 170g of oleic acid
[0302] 40g of cyclophosphamide triglyceride
[0303] Cetyl alcohol 50g
[0304] 50g of stearyl alcohol
[0305] Glyceryl monostearate and glyceryl distearate) 50g
[0306] PPD-FS was prepared according to the method in Example 1 for PPD-FS B (where the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%).
[0307] 2. Add the aqueous phase to the oil phase, stir, and then add PPD-FS to obtain the final product.
[0308] Example 29 PPD-FS film agent
[0309] 1. Prepare the raw materials according to the following proportions.
[0310] PPD-FS 10 g
[0311] Hydroxypropyl methylcellulose E5 430 g
[0312] 200 g of propylene glycol
[0313] 2500 g of purified water
[0314] PPD-FS was prepared according to the method in Example 1 for PPD-FS B (where the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%).
[0315] 2. Mix PPD-FS, hydroxypropyl methylcellulose E5, propylene glycol, and purified water evenly to make a solution, let it stand overnight, and then coat it with a film to obtain the final product.
[0316] Example 30 PPD-FS spray
[0317] 1. Prepare the raw materials according to the following proportions.
[0318] PPD-FS 10 g
[0319] β-hydroxypropyl-cyclodextrin 430 g
[0320] Add purified water to 100,000 ml
[0321] PPD-FS was prepared according to the method in Example 1 for PPD-FS B (where the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%).
[0322] 2. PPD-FS and β-hydroxypropyl-cyclodextrin are encapsulated and dissolved in water to obtain the final product.
[0323] Example 31 PPD-FS solution
[0324] 1. Prepare the raw materials according to the following proportions.
[0325] PPD-FS 10 g
[0326] β-hydroxypropyl-cyclodextrin 430g
[0327] 1000 g of glycerin
[0328] 10 g of ethylparaben
[0329] Add purified water to 10000 ml
[0330] PPD-FS was prepared according to the method in Example 1 for PPD-FS B (where the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%).
[0331] 2. PPD-FS, β-hydroxypropyl-cyclodextrin, glycerol, and ethylparaben are encapsulated and dissolved in water to obtain the final product.
[0332] Example 32 PPD-FS Powder
[0333] 2. Prepare the raw materials according to the following proportions.
[0334] PPD-FS 10 g
[0335] 1 g sodium alginate
[0336] Repackaged into 10,000 portions
[0337] PPD-FS was prepared according to the method in Example 1 for PPD-FS B (where the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%).
[0338] 2. Mix the original ginsenoside diol and sodium alginate evenly, then package them into portions to obtain the final product.
[0339] Example 33 PPD-FS Patch
[0340] 1. Prepare the raw materials according to the following proportions.
[0341] PPD-FS 10 g
[0342] Acrylic pressure-sensitive adhesive TAK87-4098 685 g
[0343] 5 g of butylated hydroxytoluene
[0344] 50 g of glyceryl monooleate
[0345] Ethanol (appropriate amount)
[0346] PPD-FS was prepared according to the method in Example 1 for PPD-FS B (where the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%).
[0347] 2. Add acrylic pressure-sensitive adhesive TAK87-4098, butylated hydroxytoluene, and glyceryl monooleate to an appropriate amount of ethanol and stir thoroughly until completely dissolved; add PPD-FS and stir evenly to obtain a drug-containing layer. Coat the drug-containing layer onto a protective layer (a polyethylene release film treated with dimethyl silicone oil), and dry at 40°C for 15 minutes to remove organic solvents. After drying, cover with a backing layer (a synthetic resin film of polyethylene, polypropylene, and polyvinyl chloride), and then cut into patches of the required size to obtain the final product.
[0348] Example 34 Ginsenoside Rg3 Gel
[0349] 1. Prepare the raw materials according to the following proportions.
[0350] Ginsenoside Rg3 10 g
[0351] Angelica extract 10 g
[0352] Carbomer 50 g
[0353] 100 g of glycerin
[0354] 50 g of triethanolamine
[0355] Add water to 1000 ml
[0356] 2. Mix ginsenoside Rg3, angelica extract, carbomer, glycerin, and 60% water until completely dissolved to form a solution. Add triethanolamine and 40% water and mix well to obtain the final product.
[0357] Example 35: Ginsenoside Diol Cream
[0358] 1. Prepare the raw materials according to the following proportions.
[0359] 10g of protopanaxadiol
[0360] Astragalus extract 10g
[0361] Aqueous phase
[0362] Sodium hexadecyl sulfate 20g
[0363] 100g of propylene glycol
[0364] 5g of benzyl alcohol
[0365] 595g of purified water
[0366] oil phase
[0367] 170g of oleic acid
[0368] 40g of cyclophosphamide triglyceride
[0369] Cetyl alcohol 50g
[0370] 50g of stearyl alcohol
[0371] Glyceryl monostearate and glyceryl distearate) 50g
[0372] 2. Add the aqueous phase to the oil phase, stir, and then add protopanaxadiol and Astragalus extract to obtain the final product.
[0373] Example 36: Ginsenoside Rg3 film-forming agent
[0374] 1. Prepare the raw materials according to the following proportions.
[0375] Ginsenoside Rg3 10 g
[0376] 5g of dragon's blood extract
[0377] Hydroxypropyl methylcellulose E5 430 g
[0378] 200 g of propylene glycol
[0379] 2500 g of purified water
[0380] 2. Mix ginsenoside diol, dragon's blood extract, hydroxypropyl methylcellulose E5, propylene glycol, and purified water evenly to make a solution. Let it stand overnight, then coat it with a film to obtain the final product.
[0381] Example 37: Ginsenoside Diol Spray
[0382] 1. Prepare the raw materials according to the following proportions.
[0383] 10 g of protopanaxadiol
[0384] β-hydroxypropyl-cyclodextrin 430 g
[0385] 10g of turmeric extract
[0386] Add purified water to 100,000 ml
[0387] 2. After encapsulating ginsenoside diol and β-hydroxypropyl-cyclodextrin, dissolve them in water, add turmeric extract and stir until dissolved.
[0388] Example 38: Ginsenoside Diol Solution
[0389] 1. Prepare the raw materials according to the following proportions.
[0390] 10 g of protopanaxadiol
[0391] β-hydroxypropyl-cyclodextrin 430g
[0392] 5g of dandelion extract
[0393] 1000 g of glycerin
[0394] 10 g of ethylparaben
[0395] Add purified water to 10000 ml
[0396] 2. After encapsulating ginsenoside diol and β-hydroxypropyl-cyclodextrin, dissolve them in water, add dandelion extract, glycerin, and ethylparaben, and stir until completely dissolved.
[0397] Example 39: Original Ginsenoside Diol Powder
[0398] 1. Prepare the raw materials according to the following proportions.
[0399] 10 g of protopanaxadiol
[0400] Honeysuckle extract 2g
[0401] Sodium alginate 8g
[0402] Repackaged into 1000 portions
[0403] 2. Mix the protopanaxadiol, honeysuckle extract, and sodium alginate evenly, then package them separately to obtain the final product.
[0404] Example 40 PPD-FS Patch
[0405] 1. Prepare the raw materials according to the following proportions.
[0406] PPD-FS 10 g
[0407] 5 g of comfrey extract
[0408] Acrylic pressure-sensitive adhesive TAK87-4098 685 g
[0409] 5 g of butylated hydroxytoluene
[0410] 50 g of glyceryl monooleate
[0411] Ethanol (appropriate amount)
[0412] PPD-FS was prepared according to the method in Example 1 for PPD-FS B (where the content ratio of Rg3, Rg5 and Rh2 is 75:22:3, and the sum of the contents of the three is 75%).
[0413] 2. Add acrylic pressure-sensitive adhesive TAK87-4098, butylated hydroxytoluene, and glyceryl monooleate to an appropriate amount of ethanol and stir thoroughly until completely dissolved. Add PPD-FS and comfrey extract, and stir evenly to obtain a drug-containing layer. Coat the drug-containing layer onto a protective layer (a polyethylene release film treated with dimethyl silicone oil), and dry at 40°C for 15 minutes to remove organic solvents. After drying, cover with a backing layer (a synthetic resin film of polyethylene, polypropylene, and polyvinyl chloride), and then cut into patches of the required size to obtain the final product.
[0414] Example 41: Ginsenoside Composition Powder
[0415] 1. Prepare the raw materials according to the following proportions.
[0416] Ginsenoside Rg3 6g
[0417] Ginsenoside Rh2 4g
[0418] 1g grape seed extract
[0419] Pepper extract 2g
[0420] 5g sodium alginate
[0421] Repackaged into 1000 portions
[0422] 2. Mix ginsenoside Rg3, ginsenoside Rh2, grape seed extract, pepper extract, and sodium alginate evenly, then package them separately to obtain the final product.
[0423] Experimental Example 1: Effect of Ginsenoside Rg3 on the Healing of Foot Ulcers in Diabetic Rats
[0424] 1. Test materials
[0425] 1.1 Drugs and Reagents
[0426] Ginsenoside Rg3 (20220901): Dalian Fusheng Natural Medicine Development Co., Ltd.; Kangfuxin Liquid: Sichuan Good Doctor Panxi Pharmaceutical Co., Ltd.; Streptozotocin (STZ): Sigma-Aldrich, Inc., USA; Sodium Citrate Buffer: Beijing Solarbio Technology Co., Ltd.
[0427] 1.2 Animals
[0428] SPF-grade SD rats (Hunan Slack Jingda Experimental Animal Co., Ltd., Experimental Animal License No.: SCXK (Xiang) 2021-0002), male, 8 weeks old, weighing 200-250g.
[0429] 1.3 Instruments
[0430] Blood glucose meter and test strips: Roche GmbH, Germany; Electronic balance: Shanghai Precision Scientific Instruments Co., Ltd.; Digital camera: Olympus Ltd., Japan.
[0431] 2. Test methods
[0432] 2.1 Modeling and Grouping
[0433] 2.1.1 Establishment and grouping of diabetic rat model
[0434] Sixty healthy male SPF-grade SD rats were acclimatized to a standard diet and purified water for one week. Their mental state, feces, and coat color were observed. They were randomly divided into a control group (n=8) and a model group (n=52).
[0435] The control group continued to be fed regular feed and purified water, with free access to food and water.
[0436] The model group was fed a high-fat, high-sugar diet for 2 weeks. After fasting but not watering, 1% streptozotocin was injected intraperitoneally at a dose of 65 mg / kg. The high-fat, high-sugar diet and purified water were continued. Blood glucose was measured by tail vein blood collection at 72 h, 7 d, and 14 d. Rats with fasting blood glucose below the target were excluded. Rats with random blood glucose ≥16.7 mmol / L were considered to have successfully modeled the virus.
[0437] Forty successfully modeled diabetic rats were randomly selected and divided into five groups of eight each: the model group, the control group (Kangfuxin liquid), and the low-, medium-, and high-dose groups of ginsenoside Rg3 solution. All rats in each group were marked and weighed.
[0438] 2.1.2 Establishment of a diabetic rat paw ulcer model
[0439] The successfully modeled diabetic rats were anesthetized with 3% sodium pentobarbital. After successful anesthesia, the rat paws were disinfected with 75% alcohol. A 6mm diameter full-thickness skin defect was excised from the center of the sole of the paw using a skin sampler, reaching the muscle fascia layer. The wound edges were trimmed, and hemostasis was achieved with gauze pressure. An indwelling dressing was then applied to prevent contamination by other bacteria. The rats were placed on a warming pad to allow them to recover naturally before being placed in cages for observation. Starting the next day, the skin wound was wiped with 50% glacial acetic acid once daily for 7 consecutive days to induce ulceration, thus establishing a diabetic rat paw ulcer model.
[0440] 2.2 Detection Method
[0441] Ginsenoside Rg3 was prepared into solutions with concentrations of 1 mg / mL, 3 mg / mL, and 5 mg / mL according to the method described in Example 7, and was kept for later use.
[0442] In both the blank control group and the model group, the ulcer wounds of rats were wiped with an equal volume of physiological saline once a day. In the control group, the wounds were wiped with physiological saline and then Kangfuxin solution was applied. In the low-dose group (1 mg / mL), medium-dose group (3 mg / mL), and high-dose group (5 mg / mL) of ginsenoside Rg3, the wounds were wiped with physiological saline and then ginsenoside Rg3 solution was applied. The wounds were covered with six layers of medical gauze and fixed with medical elastic bandages for 9 consecutive days.
[0443] Three rats (3 x 2) were randomly selected from each group and sacrificed after 5 and 9 days of intervention, respectively, for subsequent testing in Experiment 6. The specific experimental procedure was as follows: Eight animals per group. On day 5, after completing the healing rate test for each group of eight rats, three rats were randomly sacrificed for testing in Experiment 6; on day 7, the healing rate test for the remaining five rats in each group was completed; on day 9, the healing rate test for the remaining five rats in each group was completed, and then three more rats were randomly sacrificed for testing in Experiment 6.
[0444] 2.2.1 Wound healing rate
[0445] Each group of animals underwent dressing changes every morning. After treatment, the wound was covered with six layers of medical gauze and secured with medical elastic bandages to remove contamination. The wound area on day 0 was taken as 100%, and the wound area of each group was quantified on days 1, 3, 5, 7, and 9. The size of the wound was calculated using FijiImage J images, and the wound healing rate was calculated. The results are shown in Table 1.
[0446] Wound healing rate = (Initial wound area - Wound area on day n after drug administration) / Initial wound area × 100%
[0447] 3. Test Results
[0448] Compared with the control group, the wound tissue in the model group showed significantly delayed healing.
[0449] Compared with the model group, the wound healing rate of the control group and each dose group of ginsenoside Rg3 was significantly improved, with the medium dose group showing a more significant difference (P<0.05).
[0450] Table 1. Wound healing rate of diabetic foot ulcer rats treated with Rg3 ( )
[0451]
[0452] Note: *P<0.05, **P<0.01 compared with the model group.
[0453] The results in Table 1 show that the ginsenoside Rg3 of the present invention can effectively promote the healing of diabetic ulcers, with a preferred concentration of 3 mg / mL.
[0454] Experimental Example 2: Effect of the combination of ginsenoside Rg3 and ginsenoside Rh2 on the healing of paw ulcers in diabetic rats.
[0455] 1. Test materials
[0456] 1.1 Drugs and Reagents
[0457] Ginsenoside Rg3 (20221001): Dalian Fusheng Natural Medicine Development Co., Ltd.; Ginsenoside Rh2 (20221001): Dalian Fusheng Natural Medicine Development Co., Ltd.; Befuxin (Recombinant Bovine Basic Fibroblast Growth Factor Topical Gel): Zhuhai Yisheng Biopharmaceutical Co., Ltd.; Streptozotocin (STZ): Sigma-Aldrich, Inc., USA; Sodium Citrate Buffer: Beijing Solarbio Technology Co., Ltd.
[0458] 1.2 Animals
[0459] Same as in Experiment 1.
[0460] 1.3 Instruments
[0461] Same as in Experiment 1.
[0462] 2. Method
[0463] 2.1 Modeling and Grouping
[0464] 2.1.1 Establishment and grouping of diabetic rat model
[0465] The procedure was the same as in Experiment 1. There were 8 rats in the blank group and 40 rats in the model group.
[0466] Rats that successfully modeled diabetes were randomly divided into 5 groups of 8 rats each: model group, control group, low-dose group, medium-dose group, and high-dose group of ginsenoside Rg3 + ginsenoside Rh2 combination. Rats in each group were marked and weighed.
[0467] 2.1.2 Establishment of a diabetic rat paw ulcer model
[0468] The method for establishing the diabetic rat paw ulcer model is the same as that in Experiment 1.
[0469] 2.2 Test Methods
[0470] Following the method described in Example 10, gels with total concentrations of 1 mg / mL, 3 mg / mL, and 5 mg / mL were prepared using a combination of ginsenoside Rg3 and ginsenoside Rh2 (Rg3 to Rh2 in a weight ratio of 75:25) for later use.
[0471] In the blank control group and the model group, the ulcer wounds of rats were wiped with physiological saline. In the control group, after cleaning with physiological saline, Befuxin gel was applied to the ulcer wounds. In each dose group of the ginsenoside Rg3 + ginsenoside Rh2 combination, after cleaning with physiological saline, the ginsenoside Rg3 + ginsenoside Rh2 combination gel was applied to the ulcer wounds. The wounds were covered with six layers of medical gauze and fixed with medical elastic bandages for 9 days.
[0472] Three rats were randomly selected from the medium-dose group of the ginsenoside Rg3 + ginsenoside Rh2 combination. They were sacrificed after 5 days and 9 days of intervention for subsequent test results (Example 6).
[0473] 2.2.1 Wound healing rate
[0474] The frequency and method of dressing changes, the method of wound area measurement and wound healing rate calculation were the same as in Experiment 1, and the results are shown in Table 2.
[0475] 3. Experimental Results
[0476] Compared with the control group, the wound tissue in the model group showed significantly delayed healing;
[0477] Compared with the model group, the wound healing rate of the control group and the various dose groups of ginsenoside Rg3 + ginsenoside Rh2 combination was significantly improved, with the medium dose group showing a more significant difference (P < 0.05).
[0478] Table 2. Wound healing rate of diabetic foot ulcer rats treated with Rg3+Rh2 ( )
[0479]
[0480] Note: *P<0.05, **P<0.01 compared with the model group.
[0481] The results in Table 2 show that the ginsenoside Rg3 + ginsenoside Rh2 composition of the present invention can effectively promote the healing of diabetic ulcers, with a preferred total concentration of 3 mg / mL.
[0482] Comparing the results of Experiment 1 and Experiment 2, and considering the significantly higher price of ginsenoside Rg3 compared to ginsenoside Rh2, the combination of ginsenoside Rg3 and ginsenoside Rh2 offers a greater cost advantage.
[0483] Experimental Example 3: Effect of protopanaxadiol on the healing of paw ulcers in diabetic rats
[0484] 1. Test materials
[0485] 1.1 Drugs and Reagents
[0486] Protopanaxadiol (20221002): Dalian Fusheng Natural Medicine Development Co., Ltd.; Jinyintai (Recombinant Human Epidermal Growth Factor Topical Solution): Shenzhen Huashengyuan Gene Engineering Development Co., Ltd.; Streptozotocin (STZ): Sigma-Aldrich, USA; Sodium Citrate Buffer: Beijing Solarbio Science & Technology Co., Ltd.
[0487] 1.2 Animals
[0488] Same as in Experiment 1.
[0489] 1.3 Instruments
[0490] Same as in Experiment 1.
[0491] 2. Method
[0492] 2.1 Modeling and Grouping
[0493] 2.1.1 Establishment and grouping of diabetic rat model
[0494] The procedure was the same as in Experiment 1. There were 8 rats in the blank group and 40 rats in the model group.
[0495] Rats that successfully modeled diabetes were randomly divided into 5 groups of 8 rats each: model group, control group, low-dose ginsenoside diol group, medium-dose group, and high-dose group. Rats in each group were marked and weighed.
[0496] 2.1.2 Establishment of a diabetic rat paw ulcer model
[0497] The method for establishing the diabetic rat paw ulcer model is the same as that in Experiment 1.
[0498] 2.2 Test Methods
[0499] Protopanaxadiol was prepared into sprays with concentrations of 1 mg / mL, 3 mg / mL, and 5 mg / mL according to the method described in Example 20. Physiological saline was then placed in spray bottles for later use.
[0500] After cleaning, the rats in the blank group and model group had saline sprayed onto the ulcer wounds. The control group had saline sprayed onto the ulcer wounds, and the rats in each dose group of protopanaxadiol had saline sprayed onto the ulcer wounds. The wounds were covered with six layers of medical gauze and fixed with medical elastic bandages for 9 days.
[0501] Three rats were randomly selected from the medium-dose group of ginsenoside diol and sacrificed after 5 and 9 days of intervention for subsequent experimental tests (Case 6).
[0502] 2.2.1 Wound healing rate
[0503] The frequency and method of dressing changes, the method of wound area measurement and wound healing rate calculation were the same as in Experiment 1, and the results are shown in Table 3.
[0504] 3. Experimental Results
[0505] Compared with the control group, the wound tissue in the model group showed significantly delayed healing;
[0506] Compared with the model group, the wound healing rate of the control group and each dose group of ginsenoside diol was significantly improved, with the medium dose group showing a more significant difference (P < 0.05).
[0507] Table 3. Wound healing rate of diabetic foot ulcer rats treated with ginsenoside diol (Panaxadiol) )
[0508]
[0509] Note: *P<0.05, **P<0.01 compared with the model group.
[0510] As shown in Table 3, the original ginsenoside diol of the present invention can effectively promote the healing of diabetic ulcers, with a preferred concentration of 3 mg / mL.
[0511] Experiment 4: Effect of PPD-FS on the healing of paw ulcers in diabetic rats
[0512] 1. Test materials
[0513] 1.1 Drugs and Reagents
[0514] PPD-FS (PPD-FS C in Example 1, wherein the weight ratio of Rg3, Rg5, and Rh2 is 85:13:2, and the sum of their contents is 85%), Dalian Fusheng Natural Medicine Development Co., Ltd.; Befuxin (recombinant bovine basic fibroblast growth factor topical gel): Zhuhai Yisheng Biopharmaceutical Co., Ltd.; Streptozotocin (STZ): Sigma-Aldrich, Inc., USA; Sodium citrate buffer: Beijing Solarbio Technology Co., Ltd.
[0515] 1.2 Animals
[0516] Same as in Experiment 1.
[0517] 1.3 Instruments
[0518] Same as in Experiment 1.
[0519] 2. Method
[0520] 2.1 Modeling and Grouping
[0521] 2.1.1 Establishment and grouping of diabetic rat model
[0522] The procedure was the same as in Experiment 1. There were 8 rats in the blank group and 40 rats in the model group.
[0523] Rats that successfully modeled diabetes were randomly divided into 5 groups of 8 rats each: model group, control group, low-dose PPD-FS group, medium-dose group, and high-dose group. Rats in each group were marked and weighed.
[0524] 2.1.2 Establishment of a diabetic rat paw ulcer model
[0525] The method for establishing the diabetic rat paw ulcer model is the same as that in Experiment 1.
[0526] 2.2 Test Methods
[0527] PPD-FS was prepared into gels with concentrations of 1 mg / mL, 3 mg / mL, and 5 mg / mL according to the methods described in Examples 25-27, for later use.
[0528] In the blank control group and the model group, the ulcer wounds of rats were wiped with physiological saline. In the control group, after cleaning with physiological saline, Bepanthen gel was applied to the ulcer wounds. In the PPD-FS dosage groups, after cleaning with physiological saline, PPD-FS gel was applied to the ulcer wounds. The wounds were covered with six layers of medical gauze and fixed with medical elastic bandages for 9 days.
[0529] Three rats were randomly selected from the medium-dose PPD-FS group and sacrificed after 5 and 9 days of intervention for subsequent experimental tests (Case 6).
[0530] 2.2.1 Wound healing rate
[0531] The frequency and method of dressing changes, the method of wound area measurement and wound healing rate calculation were the same as in Experiment 1, and the results are shown in Table 4.
[0532] 3 Experimental Results
[0533] Compared with the control group, the wound tissue in the model group showed significantly delayed healing.
[0534] Compared with the model group, the wound healing rate of the control group and each dose group of PPD-FS was significantly improved, with the medium dose group showing a more significant difference (P<0.05).
[0535] Table 4. Wound healing rate of diabetic foot ulcer rats treated with PPD-FS ( )
[0536]
[0537] Note: *P<0.05, **P<0.01 compared with the model group.
[0538] The results in Table 4 show that the PPD-FS of the present invention can effectively promote the healing of diabetic ulcers, with a preferred concentration of 3 mg / mL.
[0539] Experimental Example 5: Effects of ginsenoside Rg3, ginsenoside combination (Rg3+Rh2), protopanaxadiol, and PPD-FS on the healing of paw ulcer wounds in diabetic rats.
[0540] 1. Test materials
[0541] 1.1 Drugs and Reagents
[0542] Ginsenoside Rg3 (20220901): Dalian Fusheng Natural Medicine Development Co., Ltd.; Ginsenoside Rg3 (20221001): Dalian Fusheng Natural Medicine Development Co., Ltd.; Ginsenoside Rh2 (20221001): Dalian Fusheng Natural Medicine Development Co., Ltd.; Protopanaxadiol (20221002): Dalian Fusheng Natural Medicine Development Co., Ltd.; PPD-FS (20221002, Rg3, Rg5, Rh2 weight ratio is 88:8:4), Dalian Fusheng Natural Medicine Development Co., Ltd.; Befuxin (recombinant bovine basic fibroblast growth factor topical gel): Zhuhai Yisheng Biopharmaceutical Co., Ltd.; Streptozotocin (STZ): Sigma-Aldrich, USA; Sodium citrate buffer: Beijing Solarbio Technology Co., Ltd.
[0543] 1.2 Animals
[0544] Same as in Experiment 1.
[0545] 1.3 Instruments
[0546] Same as in Experiment 1.
[0547] 2. Method
[0548] 2.1 Modeling and Grouping
[0549] 2.1.1 Establishment and grouping of diabetic rat model
[0550] The procedure was the same as in Experiment 1. There were 8 rats in the blank group and 96 rats in the model group.
[0551] Rats that successfully developed diabetes were randomly divided into 12 groups of 8 rats each: model group, control group, medium-dose ginsenoside Rg3 group, medium-dose ginsenoside combination (Rg3:Rh2=60:40), medium-dose ginsenoside combination (Rg3:Rh2=75:25), medium-dose ginsenoside combination (Rg3:Rh2=85:15), medium-dose ginsenoside combination (Rg3:Rh2=95:5), protopanaxadiol group, and medium-dose PPD-FS (Rg3:Rg5:Rh2=60:35:5), medium-dose PPD-FS (Rg3:Rg5:Rh2=75:22:3), medium-dose PPD-FS (Rg3:Rg5:Rh2=85:13:2), and medium-dose PPD-FS (Rg3:Rg5:Rh2=95) group. :3:2) Medium-dose group. Rats in each group were marked and weighed.
[0552] 2.1.2 Establishment of a diabetic rat paw ulcer model
[0553] The method for establishing the diabetic rat paw ulcer model is the same as that in Experiment 1.
[0554] 2.2 Test Methods
[0555] 2.2.1 Preparation of gelling agent
[0556] Weigh out the following ingredients separately: ginsenoside Rg3, ginsenoside composition (Rg3:Rh2=60:40), ginsenoside composition (Rg3:Rh2=75:25), ginsenoside composition (Rg3:Rh2=85:15), ginsenoside composition (Rg:Rh2=95:5), protopanaxadiol, and PPD-FS (Rg3:Rg5:Rh2=60:35:5), PPD-FS (Rg3:Rg5:Rh2=75:22:3), PPD-FS (Rg3:Rg5:Rh2=85:13:2), and PPD-FS (Rg3:Rg5:Rh2=95). Mix 3g of each of the 3:2 ratio with 6g of carbomer, 100g of glycerin, 6g of triethanolamine and an appropriate amount of water until the volume is adjusted to 1000ml to obtain the gel preparation (concentration of 3mg / ml).
[0557] 2.2.2 Medication administration procedure
[0558] In the blank control group and the model group, the ulcer wounds of rats were wiped with physiological saline. In the control group, after cleaning with physiological saline, Bepanthen gel was applied to the ulcer wounds. In each drug group, after cleaning with physiological saline, the drug gel was applied to the ulcer wounds. The wounds were covered with six layers of medical gauze and fixed with medical elastic bandages for 9 days.
[0559] 2.2.3 Wound healing rate
[0560] The frequency and method of dressing changes, the method of wound area measurement and wound healing rate calculation were the same as in Experiment 1, and the results are shown in Table 5.
[0561] 3 Experimental Results
[0562] Compared with the control group, the wound tissue in the model group showed significantly delayed healing.
[0563] Compared with the model group, the wound healing rate of the control group and the drug group was significantly improved, and the difference was statistically significant (P<0.05).
[0564] Table 5. Wound healing rates of diabetic foot ulcer rats treated with ginsenoside Rg3, ginsenoside combination (Rg3+Rh2), protopanaxadiol, and PPD-FS. )
[0565]
[0566] Note: *P<0.05, **P<0.01 compared with the model group.
[0567] The results in Table 5 show that ginsenoside Rg3, ginsenoside combination (Rg3+Rh2), protopanaxadiol and PPD-FS can effectively promote the healing of diabetic ulcers.
[0568] Experimental Example 6: Effects of ginsenoside Rg3, ginsenoside combination (Rg3+Rh2), protopanaxadiol, and PPD-FS on inflammatory factors in diabetic rat paw ulcers.
[0569] 1. Test materials
[0570] 1.1 Drugs and Reagents
[0571] See Experimental Examples 1, 2, 3, and 4.
[0572] 1.2 Animals
[0573] Same as in Experiment 1.
[0574] 1.3 Instruments
[0575] Centrifuge: Eppendorf; Rat IL-6 ELISA kit: Shanghai Renjie Biotechnology Co., Ltd.; Rat TNF-α ELISA kit: Shanghai Renjie Biotechnology Co., Ltd.; Rat IL-1β ELISA kit: Shanghai Renjie Biotechnology Co., Ltd.
[0576] 2. Method
[0577] 2.1 Modeling and Grouping
[0578] 2.1.1 Establishment and grouping of diabetic rat model
[0579] The method for establishing the diabetic rat model was the same as in Experiment 1. There were 8 rats in the blank group and 48 rats in the model group.
[0580] Rats that successfully modeled diabetes were randomly divided into 6 groups of 8 rats each: model group, control group, medium-dose ginsenoside Rg3 group, medium-dose ginsenoside Rg3 + medium-dose ginsenoside Rh2 group, medium-dose ginsenoside Rh2 group, and low-dose PPD-FS group.
[0581] Rats sacrificed 5 and 9 days after intervention in Experiment Example 1 were randomly selected from each of the following groups: blank group, model group, control group, and medium-dose ginsenoside Rg3 group, with 3*2 rats in each group.
[0582] Rats sacrificed 5 and 9 days after intervention in Experiment Example 2 were randomly selected from the dosage groups of the ginsenoside Rg3 + ginsenoside Rh2 combination.
[0583] Rats from Experiment 3 that were sacrificed after 5 and 9 days of intervention: 3*2 rats were randomly selected from the original medium-dose ginsenoside diol group;
[0584] Rats from Experiment 4 that were sacrificed 5 and 9 days after intervention: 3*2 rats were randomly selected from the medium-dose group of PPD-FS;
[0585] The ulcer tissues of the animals were washed, minced, and mixed with pre-cooled physiological saline at a volume ratio of 1:9 to prepare a 10% tissue homogenate. The homogenate was centrifuged at 3000-4000 r / min for 10 min at 4℃. The supernatant was collected, and the contents of IL-6, TNF-α, and IL-1β in the supernatant of each sample were detected by an ELISA kit. The results are shown in Table 5.
[0586] 3. Experimental Results
[0587] Compared with the control group, the levels of TNF-α, IL-6, and IL-1β in the wound tissue of rats in the model group were significantly increased (P<0.05).
[0588] Compared with the model group, the levels of IL-6, TNF-α, and IL-1β were significantly decreased in the control group, the medium-dose group of ginsenoside Rg3, the medium-dose group of ginsenoside Rg3 + ginsenoside Rh2 combination, the medium-dose group of protopanaxadiol, and the medium-dose group of PPD-FS (P<0.05).
[0589] Table 6. Levels of IL-6, TNF-α, and IL-1β in the wound tissue of diabetic foot ulcer rats ( )
[0590]
[0591] Note: *P < 0.05, **P < 0.01 compared to the model group.
[0592] The results in Table 6 show that the ginsenosides Rg3, Rg3+Rh2, protopanaxadiol, and PPD-FS of the present invention can effectively reduce inflammatory factors in wounds and improve inflammation of diabetic foot ulcers.
[0593] Experimental Example 7: Effects of ginsenoside Rg3, ginsenoside combination (Rg3+Rh2), protopanaxadiol, and PPD-FS on foot ulcer healing factors in diabetic rats.
[0594] 1. Test materials
[0595] 1.1 Drugs and Reagents
[0596] See Experimental Examples 1, 2, 3, and 4.
[0597] 2 Animals
[0598] Same as in Experiment 1.
[0599] 1.3 Instruments
[0600] Rat vascular endothelial growth factor (VEGF) ELISA kit: Shanghai Lianmai Biotechnology Co., Ltd.; Rat epidermal growth factor (EGF) ELISA kit: Shanghai Fantai Biotechnology Co., Ltd.
[0601] 2 methods
[0602] The animals in each group were the same as in Experiment 5.
[0603] The expression of relevant healing factors (VEGF and EGF) in rats of each group was detected by ELISA. An appropriate amount of ulcer tissue was weighed and homogenized with sterile PBS solution at a volume ratio of 1:9. The homogenate was centrifuged at 3000-4000 r / min for 10 min at 4℃, and the supernatant was collected and stored at 4℃. The VEGF and EGF contents of the ulcer tissue in each group of rats were determined according to the manufacturer's instructions, and the results are shown in Table 6.
[0604] 3 Results
[0605] Compared with the control group, the expression of VEGF and the secretion of EGF in the wound tissue of rats in the model group were significantly reduced (P<0.01).
[0606] Compared with the model group, the expression of VEGF and the secretion of EGF were significantly increased in the control group, the medium-dose group of ginsenoside Rg3, the medium-dose group of ginsenoside Rg3 + ginsenoside Rh2 combination, the medium-dose group of protopanaxadiol, and the medium-dose group of PPD-FS (P < 0.05).
[0607] Table 7. VEGF and EGF levels in the wound tissue of diabetic foot ulcer rats ( )
[0608]
[0609] Note: *P < 0.05, **P < 0.01 compared to the model group.
[0610] The results in Table 7 show that the ginsenosides Rg3, Rg3+Rh2, protopanaxadiol, and PPD-FS of the present invention can all promote the expression of EGF and VFGF, accelerate angiogenesis, and promote faster wound healing.
[0611] Case Study 8: PPD-FS Treatment of Diabetic Foot Ulcers
[0612] Before being used on humans, the product of this invention underwent necessary animal experiments to ensure its safety and efficacy. The inventors fully informed the participants of the product's basic research information, usage methods, expected benefits, and potential risks, ensuring that the participants were fully and truthfully informed. All participants explicitly indicated their voluntary participation and signed informed consent forms.
[0613] 1. Case 1
[0614] Male, 47 years old, with diabetes for more than 15 years, severe diabetic foot ulceration, awaiting amputation.
[0615] The transdermal cream of Example 25 of this invention is administered to the wound at a rate of 0.1 ml per square centimeter (equivalent to 1 mg of ginsenoside Rg3), covered with sterile gauze, and changed once daily. The wound essentially healed after 3 weeks, without the need for amputation (see [link to example 25]). Figure 1 c).
[0616] 2. Case 2
[0617] Male, 47 years old, with severe diabetic foot ulceration, awaiting amputation. Burns to the dorsum of the foot from a physiotherapy lamp. Three days of unsuccessful hospital treatment for burns.
[0618] In Example 25 of this invention, the transdermal cream was applied to the wound at a rate of 0.1 ml per square centimeter (equivalent to 1 mg of ginsenoside Rg3), covered with sterile gauze, and the dressing was changed once daily. After 3 weeks, the wound had essentially healed. (See...) Figure 2 Where: a: Day 0 of treatment; b: Week 1 of treatment (early debridement and anti-infection stage); c: Week 2 of treatment (granulation tissue regeneration and repair stage); d: Week 3 of treatment (basic recovery).
[0619] 3. Case 3
[0620] Male, 62 years old, with a 15-year history of diabetes, has multiple wounds on his buttocks that have failed to heal for about 10 years, oozing pus and blood. Various treatments have been tried without success.
[0621] The transdermal cream of Example 25 of this invention was administered to the wound at a rate of 0.1 ml per square centimeter (equivalent to 1 mg of ginsenoside Rg3), covered with sterile gauze, and changed daily. The effect was very significant, with near-complete healing after 3 weeks. (See...) Figure 3 ).
[0622] 4. Case 4
[0623] Male, 60 years old, with mild diabetic ulcers that have not healed for a long time.
[0624] The ointment for wound application in Example 25 of this invention is administered at a rate of 0.1 ml per square centimeter of wound (equivalent to 1 mg of ginsenoside Rg3), covered with sterile gauze, and changed once daily. Scabbing occurs in 3 days, and healing occurs in 6 days (see...). Figure 4 ).
[0625] 5. Case 5
[0626] Female, 65 years old, with a diabetic foot fracture that was improperly sutured, requiring a second surgery to fix with a steel plate.
[0627] The ointment for wound application in Example 25 of this invention was applied at a rate of 0.1 ml per square centimeter of wound (equivalent to 1 mg of ginsenoside Rg3), covered with sterile gauze, and the dressing was changed once a day. Good healing was observed within 3 weeks (see [link to original text]). Figure 5 ).
[0628] In summary, the ginsenosides Rg3, Rg3+Rh2, protopanaxadiol, and PPD-FS of this invention can significantly improve wound healing rate, reduce inflammatory factors IL-6, TNF-α, and IL-1β, and increase VEGF and EGF levels, without producing significant abnormalities in rats. This indicates that the ginsenosides Rg3, Rg3+Rh2, protopanaxadiol, and PPD-FS of this invention have a positive therapeutic effect on diabetic foot ulcers, especially inflammation, accelerate angiogenesis, and promote faster healing of diabetic ulcers. They have broad clinical prospects for the treatment of diabetic foot ulcer patients.
Claims
1. A drug for promoting the healing of diabetic ulcers, characterized in that, The drug is one or more of ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol, or PPD-FS.
2. The drug as described in claim 1, characterized in that, The drug is a composition of ginsenoside Rg3 and ginsenoside Rh2, wherein the weight ratio of ginsenoside Rg3 to ginsenoside Rh2 is (60~99):(40~1), preferably (75-85):(15-25).
3. The drug as described in claim 1, characterized in that, The PPD-FS includes ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rh2, wherein the weight ratio of ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rh2 is (60-95):(3-35):(2-5), preferably (75-85):(7-33):(3-5).
4. The drug as described in claim 1, characterized in that, It also includes one or more of the following: Angelica sinensis extract, dragon's blood extract, Astragalus membranaceus extract, turmeric extract, dandelion extract, Lithospermum erythrorhizon extract, pepper extract, honeysuckle extract, and grape seed extract.
5. The application of a ginseng extract in the preparation of a drug for treating diabetic ulcers, characterized in that, The ginseng extract is one or more of ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol, or PPD-FS.
6. The application as described in claim 5, characterized in that, The diabetic ulcer is a diabetic foot ulcer or a diabetic leg ulcer, preferably a diabetic foot ulcer.
7. The application as described in claim 5, characterized in that, The drug is composed of one or more of ginsenoside Rg3, ginsenoside Rh2, protopanaxadiol or PPD-FS and a pharmaceutically acceptable carrier.
8. The application as described in claim 5, characterized in that, The drug exists in the form of powder, lotion, solution, cream, ointment, suspension, spray, aerosol, gel, film or patch.
9. The application as described in claim 5, characterized in that, The drug is a topical preparation.
